FierceBiotech 9 ene 2026 Quanterix nabs Illumina’s CCO as new leader, but Leerink warns of ‘significant lift’ needed for turnaround
FierceBiotech 9 ene 2026 Madrigal pays $50M for Pfizer MASH drug with eye on Rezdiffra combo potential
FierceBiotech 9 ene 2026 Illumina hires former NHGRI Director Eric Green as new chief medical officer
FierceBiotech 9 ene 2026 Roche returns to MediLink with promise of $570M near-term payments for another ADC
FierceBiotech 9 ene 2026 Ollin eyes phase 3 after bispecific tops Vabysmo in early-stage trial, clearing more retinal disease faster
FierceBiotech 8 ene 2026 Longtime Charles River leader Jim Foster to retire, with COO set to take the helm
FierceBiotech 8 ene 2026 Lexeo Therapeutics, J&J team up to test heart pump technology for cardiac gene therapy delivery
FierceBiotech 8 ene 2026 Immuneering touts 64% 1-year survival, keeping wheels turning in race with Revolution
FierceBiotech 8 ene 2026 Diagonal moves forward with $125M series B round, plots first-in-human study this year